Trials / Completed
CompletedNCT01019161
An Open Label, Single Centre Mass Balance C14 Study in Patients With Acute Myeloid Leukaemia (AML)
A Phase I Open, Non-randomised, Single-centre Study to Assess the Metabolism, Excretion and Pharmacokinetics of AZD1152 and AZD1152 hQPA Following Intravenous Administration of [14C]-AZD1152 in Patients With Acute Myeloid Leukaemia (AML)
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 5 (actual)
- Sponsor
- AstraZeneca · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to assess how AZD1152 is absorbed or excreted in and out of the body in patients with Acute Myeloid Leukaemia (AML).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AZD1152 | 100mg Lyophile, 5mL Diluent IV infusion |
| DRUG | C14 AZD1152 | radiolabelled IV solution, 1.05 mg/ml presented as 15 ml fill in 20ml vial infusion |
Timeline
- Start date
- 2009-11-01
- Primary completion
- 2010-06-01
- Completion
- 2010-06-01
- First posted
- 2009-11-25
- Last updated
- 2010-10-20
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT01019161. Inclusion in this directory is not an endorsement.